

(12) **UK Patent Application** (19) **GB** (11) **2 426 581** (13) **A**

(43) Date of A Publication **29.11.2006**

(21) Application No: **0510943.4**

(22) Date of Filing: **27.05.2005**

(71) Applicant(s):
ONC-Immune Limited
(Incorporated in the United Kingdom)
Biocity Nottingham, Pennyfoot Street,
NOTTINGHAM, NG1 1GF, United Kingdom

(72) Inventor(s):
John Forsyth Russell Robertson
Tony Barnes
Andrea Murray
Caroline Chapman

(74) Agent and/or Address for Service:
Boult Wade Tennant
Verulam Gardens, 70 Gray's Inn Road,
LONDON, WC1X 8BT, United Kingdom

(51) INT CL:
G01N 33/574 (2006.01)

(52) UK CL (Edition X):
G1B BAD B300

(56) Documents Cited:
GB 2395270 A **US 5501955 A1**
US 20030049692 A1 **US 20030008332 A1**
J. Clin. Micro., Vol.12, 1980, Dahlberg, T. et al.,
"Enzyme-linked immunosorbant...", pp.185-192
Clin. Diagnostic Lab. Immunol., Vol.10, 2003, Giardina,
P. C. et al., "Effect of antigen coating...", pp.1136-1140
J. Immunol. Methods, Vol.193, 1996, Zielen, S. et al.,
"Simple determination of polysaccharide...", pp.1-7
J. Immunol. Methods, Vol. 94, 1986, Munoz, C. et al.,
"New experimental criteria...", pp.137-144
Infection Immunity, Vol.6, 1972, Carlsson, H. E. et al.,
"Titration of antibodies...", pp.703-708

(58) Field of Search:
INT CL⁷ **G01N**
Other: **Online: EPODOC, WPI, TXTE**

(54) Abstract Title: **Immunoassay methods**

(57) The invention relates to a method of detecting an antibody in a test sample comprising a bodily fluid from a mammalian subject wherein said antibody is a biological marker of a disease state or disease susceptibility, the method comprising: (a) contacting the test sample with a plurality of different amounts of an antigen specific for said antibody, (b) detecting the amount of specific binding between said antibody and said antigen, and (c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a)

GB 2 426 581 A




FIG. 1




FIG. 2

**Reactivity of normal & lung cancer plasma against p53
and NY-ESO antigens**




FIG. 3




FIG. 4




FIG. 5

4 / 7

Sample P954 Lung Cancer




FIG. 6

Sample P935 Lung Cancer




FIG. 7

5 / 7

Sample N7 (Normal)




FIG. 8a

Sample N7 (Normal)




FIG. 8b

Sample 18034 (PBC)




FIG. 9a

Sample 18034 (PBC)




FIG. 9b




FIG. 10a




FIG. 10b

IMPROVED IMMUNOASSAY METHODSField of the invention

5 The invention generally relates to the field of
diagnostic or prognostic assays and in particular relates to
optimisation of assays for the detection of antibodies in a
sample comprising patient bodily fluid, wherein such
antibodies are used as biological markers of a disease state
10 or disease susceptibility.

Background to the invention

15 Many diagnostic, prognostic and/or monitoring assays
rely on detection of a biological marker of a particular
disease state or disease susceptibility. Such biological
markers are commonly proteins or polypeptides that are
characteristic of a particular disease or associated with
susceptibility to disease.

20

 In recent years it has become apparent that antibodies,
and in particular autoantibodies, can also serve as
biological markers of disease or disease susceptibility.
Autoantibodies are naturally occurring antibodies directed
25 to an antigen which an individual's immune system recognises
as foreign even though that antigen actually originated in
the individual. They may be present in the circulation as
circulating free autoantibodies or in the form of
circulating immune complexes consisting of autoantibodies
30 bound to their target tumour marker protein. Differences
between a wild type protein expressed by "normal" cells and
an altered form of the protein produced by a diseased cell
or during a disease process may, in some instances, lead to
the altered protein being recognised by an individual's
35 immune system as "non-self" and thus eliciting an immune
response in that individual. This may be a humoral (i.e B
cell-mediated) immune response leading to the production of
autoantibodies immunologically specific to the altered
protein.

WO 99/58978 describes methods for use in the detection/diagnosis of cancer which are based on evaluating the immune response of an individual to two or more distinct tumour markers. These methods generally involve contacting
5 a sample of bodily fluid taken from the individual with a panel of two or more distinct tumour marker antigens, each derived from a separate tumour marker protein, and detecting the formation of complexes of the tumour marker antigens bound to circulating autoantibodies immunologically specific
10 for the tumour marker proteins. The presence of such circulating autoantibodies is taken as an indication of the presence of cancer.

Assays which measure the immune response of the
15 individual to the presence of tumour marker protein in terms of autoantibody production provide an alternative to the direct measurement or detection of tumour marker protein in bodily fluids. Such assays essentially constitute indirect detection of the presence of tumour marker protein. Because
20 of the nature of the immune response, it is likely that autoantibodies can be elicited by a very small amount of circulating tumour marker protein and indirect methods which rely on detecting the immune response to tumour markers will consequently be more sensitive than methods for the direct
25 measurement of tumour markers in bodily fluids. Assay methods based on the detection of autoantibodies may therefore be of particular value early in the disease process and possibly also in relation to screening of asymptomatic patients, for example in screening to identify
30 individuals "at risk" of developing disease amongst a population of asymptomatic individuals, to identify individuals who have developed a disease amongst a population of asymptomatic individuals. In addition the method based on the detection of autoantibodies may be of
35 particular value early in the disease process and possibly also may be used to identify individuals who have developed a disease amongst a population of symptomatic individuals. Furthermore, they may be useful for earlier detection of

recurrent disease. The assay methods may also be a value in selecting or monitoring therapies for a disease.

Antibodies and autoantibodies can also serve as
5 biological markers of other disease states or disease
susceptibilities, of which rheumatoid arthritis, systemic
lupus erythematosus (SLE), primary biliary cirrhosis (PBC),
autoimmune thyroiditis (eg Hashimoto's thyroiditis),
autoimmune gastritis (eg pernicious anaemia), autoimmune
10 adrenalitis (eg Addison's disease), autoimmune
hypoparathyroidism, autoimmune diabetes (eg Type 1
diabetes), myasthenia gravis are but examples.

The present inventors have recognised that when assays
15 based on detection of antibodies are used diagnostically or
prognostically to assess the disease state, disease
progression or disease susceptibility of an individual
within a population, difficulties can arise in devising a
standardised assay methodology appropriate for the whole
20 population of subjects to be screened because the absolute
amounts of antibody present vary dramatically from
individual to individual. This can produce a high incidence
of false negative results, for example amongst individuals
having a low amount of antibody. Similarly there is a
25 difficulty in scoring true positive results because the
variation in absolute amounts of antibody from individual to
individual means that it is difficult to set a threshold for
a positive assay result that is appropriate for all
individuals within the population screened.

30

The present inventors have now determined that the
performance and more specifically the clinical utility and
reliability of assays based on detection of antibodies,
particularly autoantibodies, as biological markers of
35 disease can be improved dramatically by inclusion of an
antigen titration step. By testing the sample suspected of
containing antibodies against a series of different amounts
of antigen and constructing a titration curve it is possible
to reliably identify true positive screening results

independently of the absolute amount of antibody present in the sample.

Summary of the invention

5

According to a first aspect of the invention there is provided a method of detecting an antibody in a test sample comprising a bodily fluid from a mammalian subject wherein said antibody is a biological markers of a disease state or disease susceptibility, the method comprising:

10

- (a) contacting the test sample with a plurality of different amounts of an antigen specific for said antibody,
- (b) detecting the amount of specific binding between said antibody and said antigen, and
- 15 (c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a).

15

According to a second aspect of the invention there is provided a method of detecting an antibody in a test sample comprising a bodily fluid from a mammalian subject, wherein said antibody is directed to a foreign substance introduced into said mammalian subject, the method comprising:

20

- (a) contacting the test sample with a plurality of different amounts of an antigen specific for said antibody,
- 25 (b) detecting the amount of specific binding between said antibody and said antigen, and
- (c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a).

25

30

In both aspects of the invention the mammalian subject is preferably a human.

35

In both aspects of the invention the method is preferably carried out *in vitro* on a test sample comprising a bodily fluid obtained or prepared from the mammalian subject.

Brief description of the drawings

Figure 1: Measurement of autoantibodies in serum using an antigen titration curve. Cancer patient serum 17766(C) binds strongly to the test antigen with a characteristic sigmoidal curve (—◆—) but does not bind to the negative control, VOL (—■—). In comparison, serum from a normal individual, 18052(N) does not bind to the test antigen () or to the negative control (—○—).

Figure 2: Comparison of p53 autoantibody levels in normal individuals and patients with primary breast cancer (PBC) as measured using the antigen titration assay. Autoantibody levels are expressed as the OD₆₅₀ due to binding to the test antigen (p53) minus that due to binding to the negative control. Normal cut-off (-----) was calculated as the mean plus 2 standard deviations of the normal population.

Figure 3 shows a comparison of p53 and NY-ESO autoantibody levels in normal individuals and patients with lung cancer as measured using the antigen titration assay. Autoantibody levels are expressed as the OD₆₅₀ due to binding to the test antigen (p53 or NY-ESO) minus that due to binding to the negative control. Normal cut-offs (-----) were calculated as the mean plus 2 standard deviations of the normal population.

Figure 4 shows a titration curve for detection of autoantibodies against p53 and NY-ESO in a sample of ascites fluid taken from a patient with breast cancer. This patient was tested but found not to produce autoantibodies against c-myc.

Figure 5 shows a titration curve for detection of autoantibodies against BRCA1, BRCA2 and HER2 in a sample of serum from a patient with breast cancer (ductal carcinoma in situ).

Figure 6 shows a titration curve for detection of autoantibodies against NY-ESO in a sample of serum from a patient with lung cancer. This patient was tested but found not to produce autoantibodies against p53 or c-myc.

5

Figure 7 shows a titration curve for detection of autoantibodies against NY-ESO and p53 in a sample of serum from a patient with lung cancer. This patient was tested but found not to produce autoantibodies against c-myc.

10

Figures 8(a) and 8(b) illustrate the results on two independent titration assays for autoantibodies against p53, c-myc and NY-ESO-1 in samples of serum from a "normal" subject (i.e. an individual with no evidence of cancer).

15

Figures 9(a) and 9(b) show the results of two independent titration assays carried out on samples of serum from a single patient with invasive breast cancer using a range of different antigens.

20

Figures 10(a) and 10(b) illustrate the results of titration assays in which samples of serum from a clinically normal human subject were tested for the presence of autoantibodies using biotinylated antigens BRCA2, HER2, c-myc and NY-ESO-1, non-biotinylated BRCA1 and control expression products of the "empty" vector VOL, which encodes the biotin tag but no additional antigen.

25

30 Detailed description of the invention

The invention provides an immunoassay method for detecting an antibody which serves as a biological marker for a disease state or disease susceptibility, characterised in that a sample to be tested for the presence of the antibody is tested for specific binding against different amounts of antigen specific for the antibody and a titration curve produced for antibody/antigen binding versus the amount of antigen tested.

35

The general features of immunoassays, for example ELISA, radioimmunoassays and the like, are well known to those skilled in the art (see Immunoassay, E. Diamandis and
5 T. Christopoulos, Academic Press, Inc., San Diego, CA, 1996). Immunoassays for the detection of antibodies having a particular immunological specificity generally require the use of a reagent (antigen) that exhibits specific immunological reactivity with the antibody under test.
10 Depending on the format of the assay this antigen may be immobilised on a solid support. A sample to be tested for the presence of the antibody is brought into contact with the antigen and if antibodies of the required immunological specificity are present in the sample they will
15 immunologically react with the antigen to form antibody-antigen complexes which may then be detected or quantitatively measured.

The method of the invention is characterised in that a
20 standardised sample to be tested for the presence of the antibody is tested against a plurality of different amounts of antigen (also referred to herein as a titration series). The sample is tested against at least two, and preferably at least three, four, five, six or seven different amounts of
25 the antigen. Typical assays may also include a negative control which does not contain any antigen.

In this context the term "antigen" refers to a substance comprising at least one antigenic determinant or
30 epitope capable of interacting specifically with the target antibody it is desired to detect. The antigen will typically be a naturally occurring or synthetic biological macromolecule such as for example a protein or peptide, a polysaccharide or a nucleic acid.

35

Skilled readers will appreciate that in the method of the invention the amount of antigenic determinants or epitopes available for binding to the target antibody is important for establishing a titration series. In many

assay formats the amount of antigenic determinants or epitopes available for binding is directly correlated with the amount of antigen molecules present. However, in other embodiments, such as certain solid phase assay systems, the amount of exposed antigenic determinants or epitopes may not correlate directly with the amount of antigen but may depend on other factors, such as attachment to the solid surface. In these embodiments, references herein to "different amounts of antigen" in a titration series may be taken to refer to different amounts of the antigenic determinant or epitope.

The relative or absolute amount of specific binding between antibody and antigen is determined for each different amount of antigen (antigenic determinant or epitope) used and used to plot or calculate a curve of the (relative or absolute) amount of specific binding versus the amount of antigen for each amount of antigen tested. Typical results are illustrated, by way of example only, in the accompanying Figures for detection of a number of different antibodies. The presence in the test sample of antibody reactive with the antigen used in the assay is indicated by a generally S-shaped or sigmoidal curve. The absolute amounts of specific binding between antibody and antigen are generally not material, unless it is desired to produce a quantitative measurement. For a simple yes/no determination of the presence or absence of antibodies it is sufficient only that a curve of the correct shape is produced. If there is no variation in detectable binding over the different amounts of antigen tested then this can be scored as an absence of a detectable amount of the antibody. The method of the invention can thus give a yes/no determination of presence or absence of antibody using a dimensionless proportional relationship which is independent of signal strength.

A measure of the amount of antibody present in a particular sample can, if desired, be derived from the results of antigen titration assays.

The method of the invention is advantageous for use in clinical diagnostic, prognostic, predictive and/or monitoring assays where the absolute amounts of target antibody present can vary enormously from patient-to-patient. The inventors have observed that if such assays are based on detection of antibody binding using a single amount/concentration of test antigen, patient samples containing an amount of antibody which is at the very low or the very high end of the normal physiological range of amount of antibody across the population can be missed due to limitations of the assay methodology; samples with a low amount of antibody may be scored as false negative results, whereas those with very high levels of antibody may be off the scale for accurate detection within the chosen assay methodology.

The titration assay method of the invention is also particularly suitable for the detection of antibodies/autoantibodies as biological markers of disease state or susceptibility where there is considerable patient-to-patient variation in the specificity and affinity of the antibodies/autoantibodies for target antigen. Autoantibody responses by their very nature can vary significantly from patient-to-patient, with variation occurring both in the absolute amounts of autoantibody present and in the specificity/affinity of the autoantibodies. The method of the invention can take account of this patient-to-patient variation, thus enabling a standard assay format to be developed for any given antibody/autoantibody.

Interactions between autoantibodies and their target antigens are generally of low affinity but the strength of binding may vary from patient-to-patient, as outlined above. The method of the invention is particularly suited to detection of low affinity binding, as a positive result can be inferred from the shape of the titration curve.

The method of the invention also provides a safeguard against day-to-day variation in the performance of immunoassays used for detection of autoantibodies/antibodies for diagnostic, prognostic and/or monitoring (disease state or therapy) purposes. It is often observed that there can be considerable day-to-day variation in signal strength when carrying out immunoassays for detection of antibodies in samples comprising patient bodily fluids. Such variation might arise, for example, because of differences in the way in which the samples were obtained and stored prior to testing. Such factors make it difficult to score the results of clinical assays with certainty, for example on the basis of a simple threshold value of antibody/antigen binding. The present invention minimises the effects of such day-to-day variation since a positive result for the presence of antibody is clearly evident from the shape of the titration curve, independent of signal strength.

Still further advantages of the method of the invention are that it allows dilution of the patient sample, yet still produces consistent results, and also that it will generally produce the same qualitative screening result (positive/negative) using bodily fluids from different sources in one individual (e.g. blood or serum versus ascites fluid or pleural effusion), even though the absolute concentration of antibodies may be different in the different fluids.

The method of the invention may be carried out in any suitable format which enables contact between a sample suspected of containing the antibody and multiple different amounts of an antigen. Conveniently, contact between the sample and different amounts of the antigen may take place in separate but parallel reaction chambers such as the wells of a microtitre plate. Varying amounts of the antigen can be coated onto the wells of the microtitre plate by preparing serial dilutions from a stock of antigen across the wells of the microtitre plate. The stock of antigen may be of known or unknown concentration. Aliquots of the test

sample may then be added to the wells of the plate, with the volume and dilution of the test sample kept constant in each well. The absolute amounts of antigen added to the wells of the microtitre plate may vary depending on such factors as
5 the nature of the target antibody, the nature of the sample under test, dilution of the test sample, etc, as will be appreciated by those skilled in the art. Generally the amounts of antigen and the dilution of the test sample will be selected so as to produce a range of signal strength
10 which falls within the acceptable detection range of the read-out chosen for detection of antibody/antigen binding in the method. Typical amounts and dilutions for testing of human serum samples suspected of containing anti-tumour marker autoantibodies are given in the accompanying
15 examples. Conveniently the tested amounts of antigen may vary in the range of from $0.01\mu\text{g/ml}$ to $10\mu\text{g/ml}$.

As aforesaid, it is also possible to construct a titration curve starting with a single stock of antigen even when the absolute concentration of antigen in the stock is
20 unknown. Provided that a same single stock solution is used and serially diluted in the same manner, it is possible to compare the results of separate titration assays for this antigen run on different starting test samples.

25 In a further embodiment different amounts of the antigen (antigenic determinants or epitopes) may be immobilised at discrete locations or reaction sites on a solid support. The entire support may then be brought into contact with the test sample and binding of antibody to
30 antigen detected or measured separately at each of the discrete locations or reaction sites. Suitable solid supports also include microarrays, for example arrays wherein discrete sites or spots on the array comprise different amounts of the antigen. Microarrays can be
35 prepared by immobilising different amounts of a particular antigen at discrete, resolvable reaction sites on the array. In other embodiments the actual amount of immobilised antigen molecules may be kept substantially constant but the size of the sites or spots on the array varied in order to

alter the amount of binding epitope available, providing a titration series of sites or spots with different amounts of available binding epitope. In such embodiments the two-dimensional surface concentration of the binding epitope(s)
5 on the antigen is important in preparing the titration series, rather than the absolute amount of antigen. Techniques for the preparation and interrogation of protein/peptide microarrays are generally known in the art.

10 Microarrays may be used to perform multiple assays for antibodies of different specificity on a single sample in parallel. This can be done using arrays comprising multiple sets of different antigens, each set comprising a particular antigen at multiple different amounts or concentrations.

15 The term "different antigens" encompasses antigens derived from different proteins or polypeptides (such as antigens derived from unrelated proteins encoded by different genes) and also antigens which are derived from different peptide epitopes of a single protein or polypeptide. A given
20 microarray may include exclusively sets of different antigens derived from different proteins or polypeptides, or exclusively sets of different antigens derived from different peptide epitopes of a single protein or polypeptide, or a mixture of the two in any proportion.

25 As used herein the term "bodily fluid", when referring to the material to be tested for the presence of antibodies using the method of the invention, includes *inter alia* plasma, serum, whole blood, urine, sweat, lymph, faeces,
30 cerebrospinal fluid, ascites, pleural effusion, seminal fluid, sputum, nipple aspirate, post-operative seroma or wound drainage fluid. As aforesaid, the methods of the invention are preferably carried out *in vitro* on a test sample comprising bodily fluid removed from the test
35 subject. The type of bodily fluid used may vary depending upon the identity of the antibody to be tested and the clinical situation in which the assay is used. In general, it is preferred to perform the assays on samples of serum or plasma. The test sample may include further components in

addition to the bodily fluid, such as for example diluents, preservatives, stabilising agents, buffers etc.

5 The term "antigen" is used herein in a broad sense to refer to any substance which exhibits specific immunological reactivity with a target antibody to be detected. Suitable antigens may include, but are not limited to, naturally occurring proteins, recombinant or synthetic proteins or polypeptides, synthetic peptides, peptide mimetics, etc,
10 also polysaccharides and nucleic acids.

Certain antigens may comprise or be derived from proteins or polypeptides isolated from natural sources, including but not limited to proteins or polypeptides
15 isolated from patient tissues or bodily fluids. In such embodiments the antigen may comprise substantially all of the naturally occurring protein, i.e. protein substantially in the form in which it is isolated from the natural source, or it may comprise a fragment of the naturally occurring
20 protein. To be effective as an antigen in the method of the invention any such "fragment" must retain immunological reactivity with the antibodies for which it will be used to test. Suitable fragments might, for example, be prepared by
25 chemical or enzymatic cleavage of the isolated protein.

Depending on the precise nature of the assay in which it will be used, the antigen may comprise a naturally occurring protein, or fragment thereof, linked to one or more further molecules which impart some desirable
30 characteristic not naturally present in the protein. For example, the protein or fragment may be conjugated to a revealing label, such as for example a fluorescent label, coloured label, luminescent label, radiolabel or heavy metal such as colloidal gold. In other embodiments the protein or
35 fragment may be expressed as a fusion protein. By way of example, fusion proteins may include a tag peptide at the N- or C- terminus to assist in purification of the recombinantly expressed antigen.

Depending on the format of the assay in which it is to be used the antigen may be immobilised on a solid support such as, for example, the wells of a microtitre plate, microarray beads or chips or magnetic beads. Immobilization
5 may be effected via non-covalent adsorption or covalent attachment.

Any suitable attachment means may be used provided this does not adversely affect the ability of the antigen to
10 immunologically react with the target antibody to a significant extent.

The invention is not limited to solid phase assays, but also encompasses assays which, in whole or in part, are
15 carried out in liquid phase, for example solution phase bead assays.

In one embodiment, antigens may be labelled with a ligand that would facilitate immobilisation, such as biotin.
20 The antigen can then be diluted to a suitable titration range and then allowed to react with autoantibodies in patient samples in solution. The resulting immune complexes can then be immobilised on to a solid support via a ligand-receptor interaction (e.g. biotin-streptavidin) and the
25 remainder of the assay performed as described below.

To facilitate the production of biotinylated antigens for use in the assay methods of the invention, cDNAs encoding a full length antigen, a truncated version thereof
30 or an antigenic fragment thereof may be expressed as a fusion protein labelled with a protein or polypeptide tag to which the biotin co-factor may be attached via an enzymatic reaction. Vectors for the production of recombinant biotinylated antigens are commercially available from a
35 number of sources.

As illustrated in the accompanying examples, an additional advantage of the use of the titration curve approach with biotinylated antigens is that the assay is

able to distinguish between binding of the biotin component to anti-biotin antibodies and true binding of the antigen to its cognate antibody. The inventors have observed that a significant number of the human population naturally produce
5 anti-biotin antibodies which might lead to the production of false positive results in assays based on the use of biotinylated antigen.

As aforesaid, the "immunoassay" used to detect
10 antibodies according to the invention may be based on standard techniques known in the art, with the exception that multiple amounts of antigen are used to create a titration curve. In a most preferred embodiment the immunoassay may be an ELISA. ELISAs are generally well
15 known in the art. In a typical "indirect" ELISA an antigen having specificity for the antibodies under test is immobilised on a solid surface (e.g. the wells of a standard microtiter assay plate, or the surface of a microbead or a microarray) and a sample comprising bodily fluid to be
20 tested for the presence of antibodies is brought into contact with the immobilised antigen. Any antibodies of the desired specificity present in the sample will bind to the immobilised antigen. The bound antibody/antigen complexes may then be detected using any suitable method. In one
25 preferred embodiment a labelled secondary anti-human immunoglobulin antibody, which specifically recognises an epitope common to one or more classes of human immunoglobulins, is used to detect the antibody/antigen complexes. Typically the secondary antibody will be anti-
30 IgG or anti-IgM. The secondary antibody is usually labelled with a detectable marker, typically an enzyme marker such as, for example, peroxidase or alkaline phosphatase, allowing quantitative detection by the addition of a substrate for the enzyme which generates a detectable
35 product, for example a coloured, chemiluminescent or fluorescent product. Other types of detectable labels known in the art may be used with equivalent effect.

The invention relates to a method of detecting antibodies that are biological markers of a disease state or disease susceptibility. This particular aspect of the invention preferably excludes assays designed to test for antibodies produced as a result of a vaccine challenge or immunisation protocol, other than vaccination with cancer markers. Therefore, assays according to this aspect of the invention preferably do not include assays designed to test for the presence of anti-viral or anti-bacterial antibodies following vaccination/immunisation.

In certain embodiments of the invention the antibody may be an autoantibody. As indicated above, the term "autoantibody" refers to a naturally occurring antibody directed to an antigen which an individual's immune system recognises as foreign even though that antigen actually originated in the individual. Autoantibodies include antibodies directed against altered forms of naturally occurring proteins produced by a diseased cell or during a disease process. The altered form of the protein originates in the individual but may be viewed by the individual's immune system as "non-self" and thus elicit an immune response in that individual in the form of autoantibodies immunologically specific to the altered protein. Such altered forms of a protein can include, for example, mutants having altered amino acid sequence, optionally accompanied by changes in secondary, tertiary or quaternary structure, truncated forms, splice variants, altered glycoforms etc. In other embodiments the autoantibody may be directed to a protein which is overexpressed in a disease state, for as a result of gene amplification or abnormal transcriptional regulation. Overexpression of a protein which is not normally encountered by cells of the immune system in significant amounts can trigger an immune response leading to autoantibody production. In still further embodiments the autoantibody may be directed to a fetal form of a protein which becomes expressed in a disease state. If a fetal protein which is normally expressed only in early stages of

development before the immune system is functional becomes expressed in a disease state, the fetal form may be recognised by the immune system as "foreign", triggering an immune response leading to autoantibody production.

5

In one embodiment the antibody may be an autoantibody specific for a tumour marker protein, and more particularly a "cancer-associated" anti-tumour autoantibody.

10

The term "cancer-associated" anti-tumour autoantibody refers to an autoantibody which is directed against an epitope present on forms of tumour marker proteins which are preferentially expressed in the cancer disease state. The presence of such autoantibodies is characteristic of the cancer disease state, or of pre-disposition to cancer in asymptomatic patients.

15

In preferred applications the method of the invention will be used to detect the presence of cancer-associated anti-tumour autoantibodies in human subjects or patients, and will most preferably take the form of an *in vitro* immunoassay, performed on a test sample comprising a sample of bodily fluid taken from the subject/patient. The sample of bodily fluid may be diluted in a suitable buffer or may be treated for long term storage or otherwise prior to testing.

20

25

In vitro immunoassays are non-invasive and can be repeated as often as is thought necessary to build up a profile of autoantibody production in a patient, either prior to the onset of disease, as in the screening of "at risk" individuals, or throughout the course of disease (further discussed below in relation to preferred applications of the method).

35

In particular, but non-limiting, embodiments the methods of the invention may comprise immunoassays to (simultaneously) detect two or more types of autoantibodies, each having specificity for different epitopes on the same

or related tumour marker proteins (e.g. different isoforms or variants encoded by a single gene) or for epitopes on different tumour marker proteins (meaning proteins encoded by different genes). These methods will typically involve
5 use of a panel of two or more sets of antigens, each set of antigens usually being derived from a different tumour marker protein (different in this context meaning proteins that are the products of different genes) although as noted above a set of antigens could also involve different
10 epitopes on the same tumour marker protein. A set of antigens refers to single antigen to be tested at different amounts/concentrations in the method of the invention. These methods, which may be hereinafter referred to as "panel assays", utilise a panel of two or more sets of
15 antigens to monitor the overall immune response of an individual to a tumour or other carcinogenic/neoplastic change. These methods thus detect a "profile" of the immune response in a given individual, indicating which tumour markers elicit an immune response resulting in autoantibody
20 production. The use of a panel of two or more antigens to monitor production of autoantibodies against two or more different tumour markers is generally more sensitive than the detection of autoantibodies to single markers and gives a much lower frequency of false negative results (see WO
25 99/58978 and WO 2004/044590, the contents of which are incorporated herein in their entirety by reference).

Therefore, in a non-limiting embodiment the invention provides a method of detecting two or more antibodies in a
30 test sample comprising a bodily fluid from a mammalian subject wherein at least one of said antibodies is a biological marker of a disease state or disease susceptibility, the method comprising:

(a) contacting the test sample with two or more sets of
35 antigens, wherein each one of said sets of antigens is specific for one of said antibodies to be detected in the test sample and wherein each set of antigens comprises a plurality of different amounts of said antigen,

(b) detecting the amount of specific binding between said antibodies and said antigens, and

(c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each set
5 of antigens used in step (a).

In one embodiment each of said two or more antibodies will be a biological marker of a disease state or disease susceptibility, however it is within the scope of the
10 invention to combine a titration assay for a disease marker antigen with a titration assay for any other type of antibody, which may or may not be a disease marker, in the same test sample.

15 For the avoidance of doubt, assays based on the use of a single type of antigen to detect antibodies may be referred to herein as "single marker assays", whereas assays based on the use of a panel of two or more antigens are referred to as "panel assays".

20

The method of the invention may be adapted for use in the detection of autoantibodies to essentially any tumour marker protein for which a suitable antigen may be prepared, as a single marker assay or as a component of a panel assay.
25 In particular, the method may be adapted to detect/measure autoantibodies to the epidermal growth factor receptor protein EGFR (Downward et al (1984) *Nature*. 307: 521-527; Robertson et al. (2001) *Archives of Pathology and Laboratory Medicine* 126;177-81), the glycoprotein MUC1 (Batra, S. K. et al. (1992) *Int. J. Pancreatology*. 12: 271-283) and the
30 signal transduction/cell cycle regulatory proteins Myc (Blackwood, E. M. et al. (1994) *Molecular Biology of the Cell* 5: 597-609), p53 (Matlashewski, G. et al. (1984) *EMBO J.* 3: 3257-3262; Wolf, D. et al. (1985) *Mol. Cell. Biol.* 5: 1887-1893) and ras (or Ras) (Capella, G. et al. (1991) *Environ Health Perspectives*. 93: 125-131), and also BRCA1 (Scully, R. et al. (1997) *PNAS* 94: 5605-10), BRCA2 (Sharan, S. K. et al. (1997) *Nature*. 386: 804-810), APC (Su, L. K. et al. (1993) *Cancer Res.* 53: 2728-2731; Munemitsu, S. et al.

(1995) *PNAS* 92: 3046-50), CA125 (Nouwen, E. J. et al. (1990) *Differentiation*. 45: 192-8), PSA (Rosenberg, R. S. et al. (1998) *Biochem Biophys Res Commun*. 248: 935-939), carcinoembryonic antigen CEA (Duffy, M.J. (2001) *Clin Chem*, Apr 47(4):624-30), CA19.9 (Haga, Y. et al (1989) *Clin Biochem* (1989) Oct 22(5): 363-8), NY-ESO-1 (cancer/testis antigen; Chen, Y.-T. et al., *Proc. Nat. Acad. Sci.* 94: 1914-1918, 1997), PSMA (prostate specific membrane antigen; Israeli, R. S. et al., *Cancer Res.* 53: 227-230, 1993), PSCA (prostate stem cell antigen; Reiter, R. E. et al., *Proc. Nat. Acad. Sci.* 95: 1735-1740, 1998) and EpCam (epithelial cellular adhesion molecule; Szala, S. et al., *Proc. Nat. Acad. Sci.* 87: 3542-3546, 1990), HER2 (also known as c-erbB2 Coussens, L. et al., *Science* 230: 1132-1139, 1985), CAGE (Jager D, et al., *Cancer Res.* 1999 Dec 15;59(24):6197-204; Mashino K, et al., *Br J Cancer*. 2001 Sep 1;85(5):713-20), cytokeratins (Moll R, et al., *Cell*. 1982 Nov;31(1):11-24; Braun S, et al., *N Engl J Med*. 2000; 342: 525-533), recoverin (Maeda A, et al., *Cancer Res.* 2000 Apr 1;60(7):1914-20, kallikreins (Kim H, et al., *Br J Cancer* 2001;84:643-650; Yousef GM, et al., *Tumor Biol* 2002;23:185-192); annexins (Hudelst G, et al., *Breast Cancer Res Treat.* 2004 Aug;86(3):281-91), α -fetoprotein (Stiller D, et al., *Acta Histochem Suppl.* 1986;33:225-31), GRP78 (Block TM, et al., *Proc Natl Acad Sci USA.* 2005 Jan 18;102(3):779-84; Hsu WM, et al., *Int J Cancer.* 2005 Mar 1;113(6):920-7), CA125 (Norum LF, et al., *Tumour Biol.* 2001 Jul-Aug;22(4):223-8; Perey L, et al., *Br J Cancer.* 1990 Oct;62(4):668-70; Devine PL, et al., *Anticancer Res.* 1992 May-Jun;12(3):709-17); mammoglobin (Zehentner BK, et al., *Clin Chem.* 2004 Nov;50(11):2069-76; Zehentner BK, Carter D. *Clin Biochem.* 2004 Apr;37(4):249-57), raf (Callans LS. et al., *Ann Surg Oncol.* 1995 Jan;2(1):38-42; Pratt MA, et al., *Mol Cell Biochem.* 1998 Dec;189(1-2):119-25), beta-human chorionic gonadotropin b-HCG (Ayala AR, et al., *Am J Reprod Immunol.* 1983 Apr-May;3(3):149-51; Gregory JJ Jr, et al., *Drugs.* 1999 Apr;57(4):463-7), or 4-5 antigen (Krause P, et al., *J Immunol Methods.* 2003 Dec;283(1-2):261-7). However, the

invention is not intended to be limited to the detection of autoantibodies to these particular tumour markers.

Assay methods according to the invention based on
5 detection of anti tumour-marker autoantibodies (in single
marker or panel assay form) may be employed in a variety of
different clinical situations. In particular, the method
may be used in the detection or diagnosis of cancer, in
assessing the prognosis of a patient diagnosed with cancer,
10 in predicting response to therapy, in monitoring the
progress of cancer or other neoplastic disease in a patient,
in detecting early neoplastic or early carcinogenic change
in an asymptomatic human subject, in screening a population
of asymptomatic human subjects in order either to identify
15 those subjects who are at increased risk of developing
cancer or to diagnose the presence of cancer, in predicting
the response of a cancer patient to anti-cancer treatment
(e.g. vaccination, anti-growth factor or signal transduction
therapies, radiotherapy, endocrine therapy, human antibody
20 therapy, chemotherapy), in monitoring the response of a
cancer patient to anti-cancer treatment (e.g. vaccination,
anti-growth factor or signal transduction therapies,
radiotherapy, endocrine therapy, human antibody therapy
chemotherapy), in the detection of recurrent disease in a
25 patient previously diagnosed as having cancer who has
undergone anti-cancer treatment to reduce the amount of
cancer present, or in the selection of an anti-cancer
therapy (e.g. vaccine, anti-growth factor or signal
transduction therapies, radiotherapy, endocrine therapy,
30 human antibody treatment chemotherapy), for use in a
particular patient.

The inventors have generally observed that levels of
cancer-associated autoantibodies show a positive correlation
35 with disease state (see also WO 99/58979, the contents of
which are incorporated herein by reference). Hence, when
the method of the invention is used in clinical applications
increased levels of anti-tumour marker autoantibodies, as

compared to suitable controls, are generally taken as an indication of the cancer disease state.

For example, when the immunoassays are used in the
5 diagnosis of cancer, the presence of an elevated level of
autoantibodies, as compared to "normal" control individuals,
is taken as an indication that the individual has cancer.
The "normal" control individuals will preferably be age-
matched controls not having any diagnosis of cancer based on
10 clinical, imaging and/or biochemical criteria.

When the immunoassays are used in predicting the
response of a cancer patient to anti-cancer treatment (e.g.
vaccination, anti-growth factor or signal transduction
15 therapies, radiotherapy, endocrine therapy, human antibody
therapy, chemotherapy), the presence of an elevated level of
autoantibodies, as compared to "normal" control individuals,
may be taken as an indication of whether or not the
individual is likely to respond to the anti-cancer
20 treatment. The "normal" control individuals will preferably
be age-matched controls not having any diagnosis of cancer
based on clinical, imaging and/or biochemical criteria. For
each of the treatments listed above, a relationship between
the level of autoantibodies compared to controls and likely
25 success of treatment can be established by observation of
the outcome of such treatment in patients whose autoantibody
status is monitored throughout treatment. The previously
established relationship may then be used to predict the
likelihood success for each treatment in a given patient
30 based on assessment of autoantibody status.

When the immunoassays are used in monitoring the
progress of cancer or other neoplastic disease in a patient,
the presence of an elevated level of autoantibodies, as
35 compared to a "normal control", is taken as an indication of
the presence of cancer in the patient. The "normal control"
may be levels of autoantibodies present in control
individuals, preferably age-matched, not having any
diagnosis of cancer based on clinical, imaging and/or

biochemical criteria. Alternatively, the "normal control" may be a "base-line" level established for the particular patient under test. The "base-line" level may be, for example, the level of autoantibodies present when either a
5 first diagnosis of cancer or a diagnosis of recurrent cancer was made. Any increase above the base-line level would be taken as an indication that the amount of cancer present in the patient has increased, whereas any decrease below the base-line would be taken as an indication that the amount of
10 cancer present in the patient has decreased. The "base-line" value may also be, for example, the level before a new treatment is commenced. A change in the level of autoantibodies would be taken as an indication of the effectiveness of the therapy. The direction of the "change"
15 (i.e. increase vs decrease) indicating a positive response to treatment will be dependent upon the precise nature of the treatment. For any given treatment the direction of the "change" in autoantibody levels indicating a positive result may be readily determined, for example by monitoring
20 autoantibody levels in comparison to other clinical or biochemical indicators of response to the treatment.

When the immunoassays are used in screening a population of asymptomatic human subjects this may be to
25 identify those subjects who are at increased risk of developing cancer, individuals having an elevated level of autoantibodies, as compared to "normal" control individuals, are identified as being "at risk" of developing cancer. The "normal" control individuals will preferably be age-matched
30 controls not identified as having any predisposition to developing cancer or any significant elevated risk of developing cancer. An exception to this may be where age itself is a major risk factor.

35 When the immunoassays are used in screening a population of asymptomatic human subjects this may be to diagnose cancer in those subjects who have already developed a cancer, individuals having an elevated level of autoantibodies as compared to "normal" control individuals

being scored as having cancer or some form of neoplastic change. The "normal" control individuals will preferably be age-matched controls not identified as having any predisposition to developing cancer or any significant elevated risk of developing cancer. An exception to this may be where age itself is a major risk factor. Alternatively, the "normal control" may be a "base-line" level established for the particular patient under test. The "base-line" level may be, for example, the level of autoantibodies present when the patient was first tested and found to have levels not elevated above a "normal control" population. Any increase thereafter against this baseline measurement would be taken as an indication of the presence of cancer in that individual. Thus the individual could through such a baseline test become their own control for future autoantibody measurement.

When the immunoassays are used in monitoring the response of a cancer patient to anti-cancer treatment (e.g. vaccination, anti-growth factor or signal transduction therapies, radiotherapy, endocrine therapy, human antibody therapy, chemotherapy), the presence of an altered level of autoantibodies after treatment is taken as an indication that the patient has responded positively to the treatment. A base-line level of autoantibodies taken before treatment is commenced may be used for comparison purposes in order to determine whether treatment results in an "increase or decrease" in autoantibody levels. A change in the level of autoantibodies would be taken as an indication of the effectiveness of the therapy. The direction of the "change" (i.e. increase vs decrease) indicating a positive response to treatment will be dependent upon the precise nature of the treatment. For any given treatment the direction of the "change" in autoantibody levels indicating a positive result may be readily determined, for example by monitoring autoantibody levels in comparison to other clinical or biochemical indicators of response to the treatment.

The method of the invention may used in predicting and/or monitoring response of an individual to essentially any known anti-cancer treatment. This includes, for example human antibody therapy wherein monoclonal or polyclonal antibodies are infused into the patient, a non-limiting specific example being treatment with the anti-growth factor antibody Herceptin™ (Baselga, J., D. Tripathy et al., J Clin Oncol., 14(3), 737-744, 1996). The presence of a natural autoantibody response may enhance or inhibit the effectiveness of treatment with artificially infused therapeutic antibodies. Using the method of the invention it is possible to correlate response to any anti-cancer treatment, including antibody therapy, with natural levels of autoantibodies prior to and over the course of the treatment in any patient or group of patients. This knowledge may then in turn be used to predict how other patients (or the same patient in the case of repeated treatment) will respond to the same treatment.

When the immunoassays are used in detection of recurrent disease, the presence of an increased level of autoantibodies in the patient, as compared to a "normal control", is taken as an indication that disease has recurred. The "normal control" may be levels of autoantibodies present in control individuals, preferably age-matched not having any diagnosis of cancer based on clinical, imaging and/or biochemical criteria. Alternatively, the "normal control" may be a "base-line" level established for the particular patient under test. The "base-line" level may be, for example, the level of autoantibodies present during a period of remission from disease based on clinical, imaging and/or biochemical criteria.

The assay method of the invention may be applied in the detection of many different types of cancer, of which examples are breast, bladder, colorectal, prostate, lung, pancreatic and ovarian cancers. The assays may complement existing methods of screening and surveillance. For

example, in the case of primary breast cancer immunoassays for autoantibodies could be used to alert clinicians to biopsy small lesions on mammograms which radiographically do not appear suspicious or to carry out breast imaging or to repeat imaging earlier than planned. In the clinic, the assay methods of the invention are expected to be more objective and reproducible compared to current imaging techniques (i.e. mammography and ultrasound), the success of which can be operator-dependent.

10

"Panel assays" may be tailored having regard to the particular clinical application. A panel of antigens for detection of autoantibodies to at least p53 and c-erbB2 is particularly useful for many types of cancer and can optionally be supplemented with other markers having a known association with the particular cancer, or a stage of the particular cancer, to be detected. For example for breast cancer the panel might include MUC 1 and /or c-myc and/or BRCA1 and/or BRCA2 and/or PSA whereas bladder cancer the panel might optionally include MUC 1 and/or c-myc, for colorectal cancer ras and/or APC, for prostate cancer PSA and/or BRCA 1 and/or BRCA2 or for ovarian cancer BRCA1 and/or BRCA2 and/or CA125. There are other preferred embodiments in which p53 or c-erbB2 are not necessarily essential.

25

In the case of breast cancer suitable panels could be selected from the following:

30 p53 and MUC 1 with optional c-erbB2 and/or c-myc, and/or BRCA1 and/or BRCA2 and/or PSA and/or NY-ESO-1 and/or BRC1;
p53 and c-myc with optional c-erbB2 and/or MUC1 and/or BRCA1 and/or BRCA2 and/or PSA and/or NY-ESO-1 and/or BRC1;
p53 and BRCA1 with optional c-erb2 and/or MUC 1 and/or c-myc
35 and/or BRCA2 and/or PSA and/or NY-ESO-1 and/or BRC1;
p53 and BRCA2 with optional c-erbB2 and/or MUC 1 and/or c-myc and/or BRCA1 and/or PSA and/or NY-ESO-1 and/or BRC1;
c-erbB2 and MUC 1 with optional p53 and/or c-myc, and/or BRCA1 and/or BRCA2 and/or PSA and/or NY-ESO-1 and/or BRC1;

c-erbB2 and c-myc with optional p53 and/or MUC1 and/or BRCA1 and/or BRCA2 and/or PSA and/or NY-ESO-1 and/or BRC1;
c-erbB2 and BRCA1 with optional p53 and/or MUC 1 and/or c-myc and/or BRCA2 and/or PSA and/or NY-ESO-1 and/or BRC1;
5 c-erbB2 and BRCA2 with optional p53 and/or MUC 1 and/or c-myc and/or BRCA1 and/or PSA;
p53, c-myc, NY-ESO-1 and BRCA2.

10 In the case of colorectal cancer suitable panels could be selected for example from the following:
p53 and ras with optional c-erbB2 and/or APC;
p53 and APC with optional c-erbB2 and/or Ras;
Ras and APC with optional p53 and/or c-erbB2
Such panels might also include CEA or CA19-9.

15

In the case of prostate cancer suitable panels could be selected for example from the following:
p53 and PSA with optional BRCA1 and/or BRCA2 and/or c-erbB2;
c-erbB2 and PSA with optional p53 and/or BRCA1 and/or BRCA2;
20 PSMA, PSCA and kallikreins.

In the case of ovarian cancer suitable panels could be selected for example from the following:
p53 and CA125 with optional c-erbB2 and/or BRCA1 and/or
25 BRCA2;
c-erbB2 and CA125 with optional p53 and/or BRCA1 and/or BRCA2;
HER2, annexins, CAGE and 4-5.

30 In the case of lung cancer suitable panels may be selected from:
p53 and NY-ESO-1, optionally with further markers;
HER2, annexins, CAGE and 4-5.

35 Where the method of the invention is used to perform a "panel assay" based on two or more tumour marker antigens derived from different proteins, at least one of the antigens in the panel must be tested in an assay according to the invention based on testing of multiple different

amounts of the antigen to form a titration curve. Preferably each of the antigens forming the panel is tested according to the assay of the invention and a titration curve plotted/calculated for each individual antigen in the panel.

The invention also contemplates that a titration assay for detection of at least one anti-tumour marker antibody may be used in combination with an assay designed to detect at least one tumour marker *protein* (which may be related or unrelated to the antigen used in the titration assay) in the same patient sample. Thus assays for anti-tumour marker autoantibodies and assays for tumour marker proteins may be performed in parallel on a single patient sample.

In a further embodiment, the immunoassay method of the invention may be used in the selection of an anti-cancer vaccine for use in a particular patient. In this embodiment a sample of bodily fluid taken from the patient is tested using a panel of two or more antigens, each corresponding to a different tumour marker protein, in order to determine the relative strength of the patient's immune response to each of the different tumour marker proteins. The "strength of immune response" to a given tumour marker protein or proteins is indicated by the presence and/or the amount of cancer-associated autoantibodies specific to that tumour marker protein detected using the immunoassay; where autoantibodies are quantified, the greater the level of cancer-associated auto-antibodies, the stronger the immune response. The tumour marker protein or proteins identified as eliciting the strongest immune response or strong responses in the patient (i.e. the highest level of autoantibodies) is or are then selected to form the basis of an anti-cancer vaccine for use in the patient.

The utility of the method of the invention is not limited to detection of anti-tumour autoantibodies, although the assay is particularly useful for this purpose. Cancer is just one example of a disease wherein detection of

autoantibodies may be used as a biological marker for disease state/disease susceptibility. The inventors have shown that substantial advantages are gained by the use of a titration approach to detect autoantibodies in patient samples. It is therefore reasonable to conclude that similar advantages will be gained by the use of the titration approach to detect autoantibodies that are biological markers for diseases other than cancer. The method is therefore applicable to detection of any autoantibody which serves as a biological marker for a disease state or disease susceptibility, in any disease which has been shown (or can be shown) to be associated with autoantibody production.

Other applications of the method of the invention include, but are not limited to, detection of autoantibodies that are biological markers of autoimmune disease, such as for example rheumatoid arthritis, systemic lupus erythematosus (SLE), primary biliary cirrhosis (PBC), autoimmune thyroiditis (e.g. Hashimoto's thyroiditis), autoimmune gastritis (e.g. pernicious anaemia), autoimmune adrenalitis (e.g. Addison's disease), autoimmune hypoparathyroidism, autoimmune diabetes (e.g. Type 1 diabetes) or myasthenia gravis and screening of patient samples for kidney or hepatic disease leading to insufficiency or failure of either organ, and for screening of patient samples post-transplantation to detect the presence of antibodies directed against either the diseased tissue (which has been left in-situ post-transplantation) or against the transplanted tissue.

In a further aspect the invention relates to a method of detecting an antibody in a test sample comprising a bodily fluid from a mammalian subject, wherein said antibody is directed to a foreign substance introduced into said mammalian subject, the method comprising:

(a) contacting the test sample with a plurality of different amounts of an antigen specific for said antibody,

(b) detecting the amount of specific binding between said antibody and said antigen, and

(c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a).

In this aspect of the invention the titration methodology may be used to evaluate the immune response of a mammalian subject, and preferably a human subject, to any foreign substance introduced into said subject.

In one embodiment the foreign substance may be a therapeutic agent, such as for example a drug or prodrug, human antibody therapy or vaccine. The method of the invention may be used to assess whether administration of a therapeutic agent to a patient triggers an immune response leading to the production of antibodies specific for an epitope on the therapeutic agent, or a component of a delivery vehicle, excipient, carrier etc. administered with the therapeutic agent.

The precise nature of the therapeutic agent is not limiting to the invention. In non-limiting embodiments the method of the invention may be used to assess immune response to synthetic small molecules, naturally occurring substances, naturally occurring or synthetically produced biological agents, or any combination of two or more of the foregoing, optionally in combination with excipients, carriers or delivery vehicles.

In one useful embodiment the method of the invention may be used to assess the immune response to a non-target portion of a therapeutic agent or vaccine. By "non-target" portion is meant a component part of the administered therapeutic agent or vaccine which, in the case of a therapeutic agent, does not contribute directly to therapeutic activity or, in the case of a vaccine, is not intended to elicit production of antibodies in the host. The non-target portion may be present, for example, to facilitate purification of the therapeutic agent or vaccine or may be designed to assist with delivery, uptake or targeting of the therapeutic agent/vaccine. Examples of

such "non-target" portions include, but are not limited to, linkers or makers commonly attached to recombinantly expressed polypeptides such as biotin labels, histidine tags etc.

5

The invention will be further understood with reference to the following non-limiting experimental examples:

10 Example 1 - general protocol for titration of antigen in an autoantibody assay

15 Samples of (biotinylated) tumour marker antigens may be prepared by recombinant expression, following analogous methods to those described in WO 99/58978.

Briefly, cDNAs encoding the marker antigens of interest were cloned into the pET21 vector (Invitrogen) which has been modified to encode a biotin tag and a 6xhistidine tag to aid
20 in purification of the expressed protein. The resulting clones are grown in a suitable bacterial host cell (in inclusion bodies), the bacteria lysed and denatured and the expressed antigens recovered via Nickel chelate affinity columns (Hi-trap, commercially available from Amersham,
25 following manufacturer's protocol). The expressed antigens were renatured by dialysis in appropriate buffer and the yield of expressed protein assessed by SDS-PAGE, western blot and ELISA and quantitated prior to storage.

30 The negative control VOL is empty vector (i.e. no cloned cDNA) which still includes the His and biotin tag sequences)

35 GenBank accession numbers for a number of marker cDNAs are as follows:

P53: B003596

c-myc: V00568

ECD6 (HER2) extracellular domain: M11730

NY-ESO: NM_001327

BRCA2: U43746

BRCA1 delta 9-10: NM_007302

5

1. Antigens and VOL (negative control) were diluted to appropriate concentrations in 0.1 M carbonate buffer then diluted serially to form a semi-log titration range (see table 1). Antigen dilutions were dispensed at 50 μ l/well into the rows of a Falcon micotitre plate according to plate layout using an electronic multi-channel pipette. Plates were covered and stored at 4°C for 48 h.

2. Plates were washed once in PBS + 0.1% tween 20 using an automated plate washer then tapped dry on tissue paper.

3. Plates were blocked with high salt incubation buffer (HSB, PBS + 0.5M NaCl + 0.1% casein) at 200 μ l/well for one hour or until required for use (store covered at 4°C).

20

4. Serum samples were defrosted, vortexed and diluted 1/100 in HSB at room temp.

5. Plates were emptied and tapped dry on tissue paper. Each diluted serum sample was dispensed at 50 μ l/well into all wells of the microtitre plate using an electronic multi-channel pipette. Control antibodies were diluted 1/1000 in HSB and dispensed into appropriate wells of plate final plate. Plates covered and incubated for 1.5 hour at room temp with shaking.

30

6. Wash step: Plates were washed three times in PBS + 0.1% tween 20 using an automated plate washer then tapped dry on tissue paper.

35

7. Horseradish peroxidase conjugated rabbit anti-human Ig (Jackson, 1/10,000 in HSB) was dispensed at 50 μ l/well into all wells of the microtitre plate. HRP-conjugated rabbit anti-mouse Ig (1/1000 in HSB) was dispensed into control

wells containing anti-antigen antibody. Plates were then incubated at room temp for 1 hour with shaking.

8. Plates were washed as in step 6.

5

9. Pre-prepared TMB substrate was added at 50 μ l/well and plate incubated on bench for 10 min. Plates were gently tapped to mix.

10 10. Optical density of wells was determined at 650 nm using a standard plate reader protocol.

Table 1: standard plate layouts

15 P53 plates

	1	2	3	4	5	6	7	8	9	10	11	12
A	p53 10 μ g/ml			c-myc 10 μ g/ml			NY-ESO 10 μ g/ml			VOL 10 μ g/ml		
B	p53 3 μ g/ml			c-myc 3 μ g/ml			NY-ESO 3 μ g/ml			VOL 3 μ g/ml		
C	p53 1 μ g/ml			c-myc 1 μ g/ml			NY-ESO 1 μ g/ml			VOL 1 μ g/ml		
D	p53 0.3 μ g/ml			c-myc 0.3 μ g/ml			NY-ESO 0.3 μ g/ml			VOL 0.3 μ g/ml		
E	p53 0.1 μ g/ml			c-myc 0.1 μ g/ml			NY-ESO 0.1 μ g/ml			VOL 0.1 μ g/ml		
F	p53 0.03 μ g/ml			c-myc 0.03 μ g/ml			NY-ESO 0.03 μ g/ml			VOL 0.03 μ g/ml		
G	p53 0.01 μ g/ml			c-myc 0.01 μ g/ml			NY-ESO 0.01 μ g/ml			VOL 0.01 μ g/ml		
H	carbonate buffer			carbonate buffer			carbonate buffer			carbonate buffer		

BRCA plates

	1	2	3	4	5	6	7	8	9	10	11	12
A	BRCA1 10 μ g/ml			BRCA2 10 μ g/ml			ECD-6 10 μ g/ml			VOL 10 μ g/ml		
B	BRCA1 3 μ g/ml			BRCA2 3 μ g/ml			ECD-6 3 μ g/ml			VOL 3 μ g/ml		
C	BRCA1 1 μ g/ml			BRCA2 1 μ g/ml			ECD-6 1 μ g/ml			VOL 1 μ g/ml		
D	BRCA1 0.3 μ g/ml			BRCA2 0.3 μ g/ml			ECD-6 0.3 μ g/ml			VOL 0.3 μ g/ml		
E	BRCA1 0.1 μ g/ml			BRCA2 0.1 μ g/ml			ECD-6 0.1 μ g/ml			VOL 0.1 μ g/ml		
F	BRCA1 0.03 μ g/ml			BRCA2 0.03 μ g/ml			ECD-6 0.03 μ g/ml			VOL 0.03 μ g/ml		
G	BRCA1 0.01 μ g/ml			BRCA2 0.01 μ g/ml			ECD-6 0.01 μ g/ml			VOL 0.01 μ g/ml		
H	carbonate buffer			carbonate buffer			carbonate buffer			carbonate buffer		

5 Example 2 - detection of autoantibodies in primary breast
cancer

The following data were obtained from a pilot study to
assess the sensitivity and reproducibility of a panel of
10 titration autoantibody assays in primary breast cancer
(PBC). The study included serum from 17 women with no
evidence of cancer and pre-operative serum samples from 20
women with primary breast cancer. Normal and cancer samples
were age matched. One normal and three cancer samples had
15 to be removed from the study because they showed evidence of
anti-biotin antibody responses and therefore could not be
assessed using the assay in its present format.
Approximately 10% of the population is thought to develop an
immune response against biotin.

20

The assay was carried out according to the protocol given in
example 1 using the antigens p53, c-myc, NY-ESO-1 and BRCA2

Figure 1 gives examples of curves obtained when the antigen
25 titration assay was used to measure p53 autoantibodies in
serum. It can be seen that the cancer patient's serum
17766(C) binds strongly to the test antigen (p53) with a
characteristic sigmoidal curve but does not bind to the
negative control, VOL. In comparison, serum from a normal
30 individual, 18052(N) does not give a titration curve for
binding to the test antigen or the negative control.

Autoantibody levels were expressed as the optical density
(650nm) due to binding to the test antigen minus that due to
35 binding to the negative control (VOL). The normal cut-off
was calculated as the 95th percentile (mean + 2 standard
deviations) of the normal group. This is shown as the
dotted line in Figure 2, in which anti-p53 autoantibody
levels in normal individuals are compared with cancer

patients. It can be seen that the cancer group show generally higher autoantibody levels and also have a greater proportion of individuals with levels above cut-off.

5 The panel consisted of four antigens; p53, c-myc, NY-ESO-1 and BRCA2. The sensitivity of the individual assays is given in table 2 along with the combined sensitivity of the panel of four antigens in the detection of primary breast cancer (63%).

10

p53	c-myc	NY-ESO-1	BRCA2	Panel
6/17 (35%)	5/17 (29%)	4/17 (24%)	4/17 (24%)	63%

Table 2: Sensitivity of the antigen titration autoantibody assay. Autoantibodies against four different antigens were measured and the combined sensitivity of the panel calculated. Cut-off levels were calculated as mean + 2 standard deviations of the normal sample set. Individuals with anti-biotin antibody responses were excluded as not capable of assessment.

20

In order to assess whether or not the measurements obtained using the titration autoantibody assay were reproducible, assays were performed on three separate days and the results are shown in table 3. An assay was deemed to be reproducible if all three results agreed. Reproducibility of measurements made on normal serum was 94% (15/16) and 88% (14/16) in breast cancer samples.

30

	Run				Run		
Normals	A	B	C	PBCs	A	B	C
18017	-	+	+	17733	+	-	-
35 18018	-	-	-	17734 AB	+	-	-
18019	-	-	-	17735	-	-	-
18020	-	-	-	17742	+	+	+

	18021	-	-	-	17743	+	+	+
	18047	-	-	-	17744	+	+	+
	18048 AB	+	-	+	17755	-	+	-
	18049	-	-	-	17756	-	-	-
5	18050	ND	-	-	17757	-	-	-
	18051	-	-	-	17758	ND	-	-
	18052	-	-	-	17759	+	+	+
	18053	-	-	-	17766	+	+	+
	18054	-	-	-	17774	-	-	-
10	18055	-	-	-	17775 AB	+	+	-
	18056	-	-	-	17776	-	-	-
	18057	-	-	-	17777	-	-	ND
	18058	-	-	-	17796	-	-	-
					17797 AB	+	-	-
15					17832	+	+	+
					17450	-	-	-

Table 3: Reproducibility of the antigen titration assay for p53 autoantibodies. Assays were performed on three separate days (Runs A, B and C) on serum samples from patients with primary breast cancer (PBC) or normal controls. Cut-off levels were calculated on a daily basis as mean + 2 standard deviations of the normal sample set. AB denotes individuals that showed evidence of an anti-biotin antibody response and whom can not be assessed by the present assay format. An assay was deemed to be reproducible if all three results agreed. Reproducibility of the normal individuals was 94% (15/16) and the PBC patients was 88% (14/16).

30

Example 3 - detection of autoantibodies in lung cancer

Analysis of autoantibody responses against 2 antigens (p53 and NY-ESO) in a pilot lung cancer study (10 normal and 9 lung cancer plasma) revealed a detection rate of 78% (Figure 3).

35

The assay was carried out according to the general protocol of example 1, except that plasma samples were used instead of serum.

5 Positive patient samples exhibited sigmoidal titration curves similar to that shown in Figure 1. Figure 3 shows a comparison of p53 and NY-ESO autoantibody levels in normal individuals and patients with lung cancer as measured using the antigen titration assay. Normal cut-offs were
10 calculated as the mean plus 2 standard deviations of the normal population.

Example 4 - Additional titration curves

15

The following additional titration curves were all generated in assays based on the general methodology described in Example 1. The results indicate that the titration curve approach may be applied to detection of a variety of
20 different antigens, in different types of bodily fluids and in different disease (exemplified by different types of cancer) and also illustrate the advantage of the method of the invention in distinguishing between "true" and "false" positive results.

25

Figure 4 shows a titration curve for detection of autoantibodies against p53 and NY-ESO in a sample of ascites fluid taken from a patient with breast cancer. This patient was tested but found not to produce autoantibodies against
30 c-myc.

Figure 5 shows a titration curve for detection of autoantibodies against BRCA1, BRCA2 and HER2 in a sample of serum from a patient with breast cancer (ductal carcinoma in
35 situ).

Figure 6 shows a titration curve for detection of autoantibodies against NY-ESO in a sample of serum from a

patient with lung cancer. This patient was tested but found not to produce autoantibodies against p53 or c-myc.

Figure 7 shows a titration curve for detection of
5 autoantibodies against NY-ESO and p53 in a sample of serum from a patient with lung cancer. This patient was tested but found not to produce autoantibodies against c-myc.

Figures 8(a) and 8(b) illustrate the results on two
10 independent titration assays for autoantibodies against p53, c-myc and NY-ESO-1 in samples of serum from a "normal" subject (i.e. an individual with no evidence of cancer). In the assay shown in Figure 7(a) a flat line is observed with increasing amounts of antigen, indicating that the serum
15 sample does not contain autoantibodies to any of the tested antigens. When a second aliquot of the same patient serum sample was tested again using the same assay methodology the assay failed producing the anomalous results shown in Figure 7(b). The absence of the characteristic titration curve
20 with increasing amounts of antigen indicates that this is an anomalous result, rather than a true positive. Had this sample been tested in a single point assay using a single, fixed amount of antigen then it may have appeared as a "false positive" result. Thus, these results illustrate the
25 advantage of the titration curve approach in distinguishing between true and false positive results.

Figures 9(a) and 9(b) shows the results of two independent
30 titration assays carried out on samples of serum from a single patient with invasive breast cancer using a range of different antigens. This particular patient shows autoantibodies to NY-ESO-1, HER2 and BRCA2. For each positive antigen a positive assay result is indicated by increasing signal strength as the concentration of antigen
35 increases, i.e. a titrating signal.

Figures 10(a) and 10(b) illustrate the utility of the invention in distinguishing between anti-biotin responses and "true" autoantibodies to a specific antigen (i.e. a

tumour marker). In these assays samples of serum from a clinically normal human subject were tested for the presence of autoantibodies using biotinylated antigens BRCA2, HER2, c-myc and NY-ESO-1, non-biotinylated BRCA1 and control
5 expression products of the "empty" vector VOL, which encodes the biotin tag but no additional antigen. The tested individual exhibits a titrating response to both biotinylated antigens and to the empty vector VOL, which is effectively biotin alone, but no response to the non-
10 biotinylated antigen BRCA1, indicating that the "positive" results with the biotinylated markers are in fact due to the presence of anti-biotin antibodies in this individual.

Claims

1. A method of detecting an antibody in a test sample comprising a bodily fluid from a mammalian subject wherein
5 said antibody is a biological marker of a disease state or disease susceptibility, the method comprising:
(a) contacting the test sample with a plurality of different amounts of an antigen specific for said antibody,
(b) detecting the amount of specific binding between said
10 antibody and said antigen, and
(c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a).
- 15 2. The method according to claim 1 wherein the antibody is an autoantibody specific for a tumour marker protein.
3. The method according to claim 2 wherein the antigen is a tumour marker protein or an antigenic fragment or epitope
20 thereof.
4. The method according to claim 3 wherein the tumour marker protein is MUC1, MUC16, c-myc, EGRF, p53, ras, BRCA1, BRCA2, APC, HER2, PSA, CEA, CA19.9, NY-ESO-1, 4-5, CAGE,
25 PSMA, PSCA, EpCam, a cytokeratin, recoverin, a kallikrein, an annexin, AFP, GRP78, CA125, mammoglobin, or raf.
5. Use of the method of any one of claims 2 to 4 in the diagnosis, prognosis or monitoring of cancer.
30
6. Use of the method of any one of claims 2 to 4 in screening a population of asymptomatic human subjects to identify those subjects who are at increased risk of developing cancer, wherein the samples to be tested using
35 the method are samples of bodily fluid taken from the subjects, and wherein subjects having an elevated level of autoantibodies, as compared to normal control individuals, are identified as being at risk of developing cancer.

7. Use of the method of any one of claims 2 to 4 in detecting early neoplastic or early carcinogenic change in an asymptomatic human subject, wherein the sample to be tested using the method is a sample of bodily fluid taken from the subject, and wherein the presence of an elevated level of autoantibodies, as compared to normal control individuals, is taken as an indication of early neoplastic or early carcinogenic change in the subject.
8. Use of the method of any one of claims 2 to 4 in screening a population of asymptomatic human subjects to identify those subjects who have developed a cancer, wherein the samples to be tested using the method are samples of bodily fluid taken from the subjects, and wherein subjects having an elevated level of autoantibodies, as compared to normal control individuals, are diagnosed as having a cancer.
9. Use of the method of any one of claims 2 to 4 in testing a population of symptomatic human subjects to identify those subjects who have developed a cancer, wherein the samples to be tested using the method are samples of bodily fluid taken from the subjects, and wherein subjects having an elevated level of autoantibodies, as compared to normal control individuals, are diagnosed as having a cancer.
10. Use of the method of any one of claims 2 to 4 in monitoring the progress of cancer or other neoplastic disease in a patient, wherein the sample to be tested using the method is a sample of bodily fluid taken from a human patient, and wherein the presence of an elevated level of autoantibodies, as compared to a normal control, is taken as an indication of the presence of cancer in the patient.
11. Use of the method of any one of claims 2 to 4 in the detection of recurrent disease in a human patient previously diagnosed as having cancer, which patient has undergone anti-cancer treatment to reduce the amount of cancer

present, wherein the sample to be tested using the method is a sample of bodily fluid taken from the patient, and wherein the presence of an increased level of autoantibodies in the patient, as compared to a normal control, is taken as an indication that disease has recurred.

12. Use of the method of any one of claims 2 to 4 in assessment of prognosis from cancer, wherein the sample to be tested using the method is a sample of bodily fluid taken from a human patient, and wherein the presence of an elevated level of autoantibodies, as compared to a normal control, is taken as an indication of the prognosis of the patient from their cancer.

13. Use of the method of any one of claims 2 to 4 in predicting response to anti-cancer treatment, wherein the sample to be tested using the method is a sample of bodily fluid taken from a human patient, and wherein comparison of the level of autoantibodies is said patient with a previously established relationship between levels of autoantibodies and likely outcome of treatment is used to provide an indication of whether the patient will respond to such anti-cancer treatment.

14. Use according to claim 13 wherein the anti-cancer treatment is vaccination, anti-growth factor or signal transduction therapy, radiotherapy, endocrine therapy, human antibody therapy or chemotherapy.

15. Use of the method of any one of claims 2 to 4 in monitoring the response of a human cancer patient to anti-cancer treatment, wherein the sample to be tested using the method is a sample of bodily fluid taken from the patient, and wherein a change in the level of autoantibodies after treatment is taken as an indication of whether or not the patient has responded to the treatment.

16. Use according to claim 15 wherein the treatment is vaccination, anti-growth factor or signal transduction

therapy, radiotherapy, endocrine therapy, human antibody therapy or chemotherapy and a change in the level of autoantibodies after treatment is taken as an indication that the patient has responded positively to the treatment.

5

17. Use of the method of any one of claims 2 to 4 in the selection of an anti-cancer treatment for use in a particular human patient, wherein the method is carried out using a panel of two or more antigens each corresponding to a different tumour marker protein in order to determine the relative strength of the patient's immune response to each of the different tumour marker proteins, wherein the tumour marker protein or proteins identified as eliciting the strongest immune response or strong responses in the patient is or are selected to form the basis of an anti-cancer treatment for use in said patient.

18. Use according to claim 17 wherein the anti-cancer treatment is vaccination and the tumour marker protein or proteins identified as eliciting the strongest immune response or strong responses in the patient is or are selected to form the basis of an anti-cancer vaccine for use in said patient.

19. The method according to claim 1 wherein the antibody is an autoantibody characteristic of or associated with an autoimmune disease.

20. The method according to claim 19 wherein the autoimmune disease is rheumatoid arthritis, systemic lupus erythematosus (SLE), primary biliary cirrhosis (PBC), autoimmune thyroiditis, Hashimoto's thyroiditis, autoimmune gastritis, pernicious anaemia, autoimmune adrenalitis, Addison's disease, autoimmune hypoparathyroidism, autoimmune diabetes or myasthenia gravis.

21. The method according to claim 1 wherein the antibody is an autoantibody characteristic of or associated with kidney

or hepatic disease leading to insufficiency or failure of either organ.

22. The method according to claim 1 wherein the antibody is
5 directed towards an epitope present on tissue transplanted into the mammalian subject.

23. A method of detecting an antibody in a test sample comprising a bodily fluid from a mammalian subject, wherein
10 said antibody is directed to a foreign substance introduced into said mammalian subject, the method comprising:
(a) contacting the test sample with a plurality of different amounts of an antigen specific for said antibody,
(b) detecting the amount of specific binding between said
15 antibody and said antigen, and
(c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a).

24. A method according to claim 23 wherein the mammalian
20 subject is a human.

25. A method according to claim 23 or claim 24 wherein the
foreign substance is a therapeutic agent.

26. A method according to claim 25 wherein the therapeutic
agent is a drug, prodrug, or antibody therapy.

27. A method according to claim 23 or claim 24 wherein the
30 foreign substance is a vaccine.

28. A method according to claim 26 or claim 27 wherein the
foreign substance is a non-target portion of a therapeutic
agent or vaccine.

29. A method according to claim 28 wherein the non-target
35 portion is biotin.



INVESTOR IN PEOPLE

Application No: GB0510943.4

45

Examiner: Dr Jeremy Kaye

Claims searched: 1-29

Date of search: 2 September 2005

Patents Act 1977: Search Report under Section 17

Documents considered to be relevant:

Category	Relevant to claims	Identity of document and passage or figure of particular relevance
X,Y	X: 1, 19, 23 & 24; Y: 2-18, 20-22, 25-29	US 2003/0049692 A1 (LATOV ET AL.) see p.2, para.[0018] - p.3, para.[0049]
X,Y	X: 1, 19, 23 & 24; Y: 2-18, 20-22, 25-29	US 5501955 A1 (BERGMAN) see Figure 4, col.7, ll.18-21; col.8, l.32 - col.9, l.6
X,Y	X: 1, 23 & 24; Y: 2-22, 25-29	US 2003/0008332 A1 (RYAN ET AL.) see p.8, paras.[0102]-[0104]
X,Y	X: 1, 23 & 24; Y: 2-22, 25-29	J. Clin. Micro., Vol.12, 1980, Dahlberg, T. et al., "Enzyme-linked immunosorbant...", pp.185-192 see p.187, "(a) Antigen-coated tubes", "Antigen concentration and coating time"; p.188, Fig.4
X,Y	X: 1, 23 & 24; Y: 2-22, 25-29	Clin. Diagnostic Lab. Immunol., Vol.10, 2003, Giardina, P. C. et al., "Effect of antigen coating...", pp.1136-1140 see whole document
X,Y	X: 1, 23 & 24; Y: 2-22, 25-29	J. Immunol. Methods, Vol.193, 1996, Zielen, S. et al., "Simple determination of polysaccharide...", pp.1-7 see esp. p.2, "2.4 ELISA"; p.3, "3.1 Binding characteristics..."
X,Y	X: 1, 23 & 24; Y: 2-22, 25-29	J. Immunol. Methods, Vol. 94, 1986, Munoz, C. et al., "New experimental criteria...", pp.137-144 see esp. Results
X,Y	X: 1, 23 & 24; Y: 2-22, 25-29	Infection Immunity, Vol.6, 1972, Carlsson, H. E. et al., "Titration of antibodies...", pp.703-708 see esp Results; Fig.2



INVESTOR IN PEOPLE

Y	2-22, 25-29	GB2395270 A (UNIV. NOTTINGHAM) see whole document
---	-------------	--

Categories:

X	Document indicating lack of novelty or inventive step	A	Document indicating technological background and/or state of the art
Y	Document indicating lack of inventive step if combined with one or more other documents of same category	P	Document published on or after the declared priority date but before the filing date of this invention
&	Member of the same patent family	E	Patent document published on or after, but with priority date earlier than, the filing date of this application

Field of Search:

Search of GB, EP, WO & US patent documents classified in the following areas of the UKC^X :

Worldwide search of patent documents classified in the following areas of the IPC⁰⁷

G01N

The following online and other databases have been used in the preparation of this search report

Online: EPODOC, WPI, TXTE